Rasmussen, Daniel Guldager Kring http://orcid.org/0000-0003-1642-7482
Fenton, Anthony
Jesky, Mark
Ferro, Charles
Boor, Peter http://orcid.org/0000-0001-9921-4284
Tepel, Martin
Karsdal, Morten Asser
Genovese, Federica
Cockwell, Paul
Article History
Received: 11 August 2017
Accepted: 27 November 2017
First Online: 11 December 2017
Competing Interests
: D.G.K.R., M.A.K. and F.G. are full-time employees at Nordic Bioscience. Nordic Bioscience is a privately-owned, small–medium size enterprise partly focused on the development of biomarkers. None of the authors received fees, bonuses or other benefits for the work described in the manuscript. M.A.K. holds stocks in Nordic Bioscience. The patent for the ELISA used to assess endotrophin levels (the PRO-C6 ELISA) is owned by Nordic Bioscience. The funder provided support in the form of salaries for authors D.G.K.R., M.A.K. and F.G., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors report no competing financial interests relevant to this manuscript.